BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26850005)

  • 1. Arylboronic acids as dual-action FAAH and TRPV1 ligands.
    Morera E; Di Marzo V; Monti L; Allarà M; Schiano Moriello A; Nalli M; Ortar G; De Petrocellis L
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1401-5. PubMed ID: 26850005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
    Minkkilä A; Saario SM; Käsnänen H; Leppänen J; Poso A; Nevalainen T
    J Med Chem; 2008 Nov; 51(22):7057-60. PubMed ID: 18983140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.
    Maione S; Costa B; Piscitelli F; Morera E; De Chiaro M; Comelli F; Boccella S; Guida F; Verde R; Ortar G; Di Marzo V
    Pharmacol Res; 2013 Oct; 76():98-105. PubMed ID: 23911581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrahydro-β-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels.
    Ortar G; De Petrocellis L; Moriello AS; Allarà M; Morera E; Nalli M; Di Marzo V
    Bioorg Med Chem Lett; 2013 Jan; 23(1):138-42. PubMed ID: 23206861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.
    Morera E; De Petrocellis L; Morera L; Moriello AS; Ligresti A; Nalli M; Woodward DF; Di Marzo V; Ortar G
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6806-9. PubMed ID: 19875281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management.
    Qiao Z; Liu S; Zhai W; Jiang L; Ma Y; Zhang Z; Wang B; Shao J; Qian H; Zhao F; Yan L
    Eur J Med Chem; 2024 Mar; 267():116208. PubMed ID: 38325006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels.
    Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V
    Neuropsychopharmacology; 2009 Feb; 34(3):593-606. PubMed ID: 18580871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of FAAH, TRPV1, and COX2 by NSAID-serotonin conjugates.
    Rose TM; Reilly CA; Deering-Rice CE; Brewster C; Brewster C
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5695-5698. PubMed ID: 25467164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
    Ortar G; Cascio MG; De Petrocellis L; Morera E; Rossi F; Schiano-Moriello A; Nalli M; de Novellis V; Woodward DF; Maione S; Di Marzo V
    J Med Chem; 2007 Dec; 50(26):6554-69. PubMed ID: 18027904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice.
    Costa B; Bettoni I; Petrosino S; Comelli F; Giagnoni G; Di Marzo V
    Pharmacol Res; 2010 Jun; 61(6):537-46. PubMed ID: 20138997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonvulsant effects of N-arachidonoyl-serotonin, a dual fatty acid amide hydrolase enzyme and transient receptor potential vanilloid type-1 (TRPV1) channel blocker, on experimental seizures: the roles of cannabinoid CB1 receptors and TRPV1 channels.
    Vilela LR; Medeiros DC; de Oliveira AC; Moraes MF; Moreira FA
    Basic Clin Pharmacol Toxicol; 2014 Oct; 115(4):330-4. PubMed ID: 24674273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis.
    Navarria A; Tamburella A; Iannotti FA; Micale V; Camillieri G; Gozzo L; Verde R; Imperatore R; Leggio GM; Drago F; Di Marzo V
    Pharmacol Res; 2014 Sep; 87():151-9. PubMed ID: 24861565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPV1 blockers as potential new treatments for psychiatric disorders.
    Iglesias LP; Aguiar DC; Moreira FA
    Behav Pharmacol; 2022 Feb; 33(1):2-14. PubMed ID: 33136616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoyl-serotonin (AA-5-HT).
    Bashashati M; Fichna J; Piscitelli F; Capasso R; Izzo AA; Sibaev A; Timmermans JP; Cenac N; Vergnolle N; Di Marzo V; Storr M
    Neurogastroenterol Motil; 2017 Dec; 29(12):. PubMed ID: 28695708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold.
    Morera L; Labar G; Ortar G; Lambert DM
    Bioorg Med Chem; 2012 Nov; 20(21):6260-75. PubMed ID: 23036333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vanilloid receptor 1 (TRPV1/VR1) co-localizes with fatty acid amide hydrolase (FAAH) in retinal amacrine cells.
    Zimov S; Yazulla S
    Vis Neurosci; 2007; 24(4):581-91. PubMed ID: 17686199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
    Holtfrerich A; Hanekamp W; Lehr M
    Eur J Med Chem; 2013 May; 63():64-75. PubMed ID: 23455058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors.
    Sunduru N; Svensson M; Cipriano M; Marwaha S; Andersson CD; Svensson R; Fowler CJ; Elofsson M
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):513-521. PubMed ID: 28114819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unprecedented reversible mode of action of β-lactams for the inhibition of human fatty acid amide hydrolase (hFAAH).
    Feledziak M; Michaux C; Lambert DM; Marchand-Brynaert J
    Eur J Med Chem; 2013 Feb; 60():101-11. PubMed ID: 23287055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH).
    Aghazadeh Tabrizi M; Baraldi PG; Ruggiero E; Saponaro G; Baraldi S; Romagnoli R; Martinelli A; Tuccinardi T
    Eur J Med Chem; 2015 Jun; 97():289-305. PubMed ID: 26002335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.